Evaluating the Transporter Protein Inhibitor Probenecid In Patients With Epilepsy

• Status: Terminated
• Trial end date: 2011-06-01
• Target enrollment: 0
• Participant gender: Male

Summary

The study is being done to understand why some patients with epilepsy (disease of recurrence of seizures) do not respond very well to drug treatment with anticonvulsants.

Despite the availability of many anticonvulsants, about 30% of patients with epilepsy are resistant to them. The cause of the resistance is not clear, but one of the reasons could be an increased amount of proteins in the cells of the body called transporter proteins.

Transporter proteins are a group of proteins that help to defend the body against toxins, including drugs, by pumping them out of the cells. Studies have shown that the number of transporter proteins is higher in the parts of the brain that trigger seizures when compared to other parts of the brain.

Studies in animals have shown that taking an anticonvulsant with an inhibitor (meaning "to stop" or "to reduce") of a transporter protein can increase the concentration of that anticonvulsant inside the brain cells. The main purpose of the study is to determine if taking an anticonvulsant and a transporter protein inhibitor will change the brain concentration of the anticonvulsant.

In this study, a single dose of phenytoin (Dilantin® is a brand name anticonvulsant which has phenytoin as its active ingredient), a commonly used anticonvulsant, will be given once by itself, and then will be given a separate time with a single (i.e. one time only) dose of probenecid. Probenecid, a medicine used commonly to treat gout (a disease of increased uric acid), is known to be an inhibitor of transporter proteins. The study will use electroencephalogram or EEG (recording of brain wave activities) to determine if the EEG pattern when probenecid is given, will be different from the EEG pattern when phenytoin is given alone. This will suggest that probenecid has affected the brain concentration of phenytoin.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Jim McAuley
• Treatments: Phenytoin; Probenecid

Criteria

Inclusion Criteria:

• Men with pharmacoresistant partial epilepsy defined as failure of two or more AEDs at a reasonable therapeutic dose

• Patient is able to understand and sign a consent form and able to keep a seizure calendar

• Patient is older than 18 years of age

• Patient is otherwise healthy by laboratory and physical examination

Exclusion Criteria:

• Patient is currently taking phenytoin

• Patient has a history of an adverse reaction to phenytoin

• Patient has a history of gout disease, peptic ulcer disease, blood dyscrasias, or uric acid kidney stones

• Patient has an allergy to sulfa drugs or probenecid

• Patient has been exposed to probenecid or another known transporter inhibitor (verapamil, progesterone, etc) in the three months prior to enrollment

• Patient has a history of renal impairment (creatinine clearance < 50 ml/min)

• Patient has a history of diabetes and is taking oral sulfonylurea agents